Betulinic Acid: Recent Advances in Chemical Modifications, Effective Delivery, and Molecular Mechanisms of a Promising Anticancer Therapy

Chemical Biology and Drug Design

Volumn 87, Issue 4, 2016, Pages 517-536

  Ali Seyed, Mohamed ^a,b   Jantan, Ibrahim ^a   Vijayaraghavan, Kavitha ^b   Bukhari, Syed Nasir Abbas ^a  

^a UNIVERSITI KUALA LUMPUR   (Malaysia)

^b B S ABDUR RAHMAN CRESCENT INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

anticancer agents; apoptosis; BetA; betulin; betulinic acid; natural products; pipeline drugs; plant derivatives

Indexed keywords

ANTINEOPLASTIC AGENT; BETULIC ACID; TRITERPENE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL DEATH; CELL STRESS; CHEMICAL MODIFICATION; DRUG ACETYLATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; DRUG OXIDATION; DRUG PURIFICATION; DRUG SYNTHESIS; DRUG TRANSFORMATION; ESTERIFICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOMERIZATION; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYTOCHEMISTRY; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION INITIATION; CHEMISTRY; DRUG EFFECTS;

ANTINEOPLASTIC AGENTS; MITOCHONDRIA; TRITERPENES;

EID: 84960449211     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12682     Document Type: Review

References (213)

1. Chen W., Zheng R., Zhang S., Zhao P., Zeng H., Zou X., (2014) Report of cancer incidence and mortality in China. Ann Transl Med; 2: 61.
2. GLOBOCAN (IARC). 2012 Section of Cancer Surveillance. http://globocan.iarc.fr/Default.aspx.
3. Jemal A., Center M.M., DeSantis C., Ward E.M., (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev; 19: 1893-1907.
4. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A., (2015) Global cancer statistics, 2012. CA Cancer J Clin; 65: 87-108.
5. Cragg G.M., Kingston D.G.I., Newman D.J., (eds) (2005) Anticancer Agents from Natural Products. Boca Raton, FL: Brunner-Routledge Psychology Press, Taylor & Francis Group.
6. Newman D.J., Cragg G.M., Snader K.M., (2003) Natural products as sources of new drugs over the period 1981-2002. J Nat Prod; 66: 1022-1037.
7. Shakeri A., Sahebkar A., (2015) Anti-cancer products from marine sponges: Progress and promise. Recent Pat Drug Deliv Formul; 9: 187-188.
8. McRae J., Yang Q., Crawford R., Palombo W., (2007) Review of the methods used for isolating pharmaceutical lead compounds from traditional medicinal plants. Environmentalist; 27: 165-174.
9. Gali-Muhtasib H., Hmadi R., Kareh M., Tohme R., Darwiche N., (2015) Cell death mechanisms of plant-derived anticancer drugs: Beyond apoptosis. Apoptosis; 20: 1531-1562.
10. Sharma S.B., Gupta R., (2015) Drug development from natural resource: A systematic approach. Mini Rev Med Chem; 15: 52-57.
11. Fulda S., (2010) Modulation of apoptosis by natural products for cancer therapy. Planta Med; 76: 1075-1079.
12. Khazir J., Singh P.P., Reddy D.M., Hyder I., Shafi S., Sawant S.D., Chashoo G., Mahajan A., Alam M.S., Saxena A.K., Arvinda S., Gupta B.D., Kumar H.M., (2013) Natural products as lead compounds in drug discovery. J Asian Nat Prod Res; 15: 764-788.
13. Sisodiya P.S., (2013) Plant derived anticancer agents: A review. Int J Res Dev Pharm Life Sci; 2: 293-308.
14. Hosseini A., Ghorbani A., (2015) Cancer therapy with phytochemicals: Evidence from clinical studies. Avicenna J Phytomed; 5: 84-97.
15. Simoben C.V., Ibezim A., Ntie-Kang F., Nwodo J.N., Lifongo L.L., (2015) Exploring cancer therapeutics with natural products from African medicinal plants, part I: Xanthones, quinones, steroids, coumarins, phenolics and other classes of compounds. Anticancer Agents Med Chem; 15: 1092-1111.
16. Mishra B.B., Tiwari V.K., (2011) Natural products: An evolving role in future drug discovery. Eur J Med Chem; 46: 4769-4807.
17. Dall'Acqua S., (2014) Natural products as antimitotic agents. Curr Top Med Chem; 14: 2272-2285.
18. Kowalski R.J., Giannakakou P., Gunasekera S.P., Longley R.E., Day B.W., Hamel E., (1997) The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol; 52: 613-622.
19. Liu Y., Guo M., (2014) Chemical proteomic strategies for the discovery and development of anticancer drugs. Proteomics; 14: 399-411.
20. Proudfoot J.R., (2002) Drugs, leads, and drug-likeness: An analysis of some recently launched drugs. Bioorg Med Chem Lett; 12: 1647-1650.
21. Udeani G.O., Zhao G.M., Geun Shin Y., Cooke B.P., Graham J., Beecher C.W., Kinghorn A.D., Pezzuto J.M., (1999) Pharmacokinetics and tissue distribution of betulinic acid in CD-1 mice. Biopharm Drug Dispos; 20: 379-383.
22. Butler M.S., Robertson A.A., Cooper M.A., (2014) Natural product and natural product derived drugs in clinical trials. Nat Prod Rep; 31: 1612-1661.
23. Jonnalagadda S.C., Corsello M.A., Sleet C.E., (2013) Betulin-betulinic acid natural product based analogs as anti-cancer agents. Anticancer Agents Med Chem; 13: 1477-1499.
24. Gheorgheosu D., Duicu O., Dehelean C., Soica C., Muntean D., (2014) Betulinic acid as a potent and complex antitumor phytochemical: A minireview. Anticancer Agents Med Chem; 14: 936-945.
25. Csuk R., (2014) Betulinic acid and its derivatives: A patent review (2008-2013). Expert Opin Ther Pat; 24: 913-923.
26. Gershenzon J., Dudareva N., (2007) The function of terpene natural products in the natural world. Nat Chem Biol; 3: 408-414.
27. Dzubak P., Hajduch M., Vydra D., Hustova A., Kvasnica M., Biedermann D., Markova L., Urban M., Sarek J., (2006) Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep; 23: 394-411.
28. Miles D.H., Kokpol U., Zalkow L.H., Steindel S.J., Nabors J.B., (1974) Tumor inhibitors. I. Preliminary investigation of antitumor activity of sarracenia flava. J Pharm Sci; 63: 613-615.
29. Kingston D.G., Munjal R.C., (1978) Plant anticancer agents. VIII. Constituents of Inga punctata. Lloydia; 41: 499-500.
30. Trumbull E.R., Bianchi E., Eckert D.J., Wiedhopf R.M., Cole J.R., (1976) Tumor inhibitory agents from Vauquelinia corymbosa (Rosaceae). J Pharm Sci; 65: 1407-1408.
31. Eiznhamer D.A., Xu Z.Q., (2004) Betulinic acid: A promising anticancer candidate. IDrugs; 7: 359-373.
32. Cichewicz R.H., Kouzi S.A., (2004) Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med Res Rev; 24: 90-114.
33. Yogeeswari P., Sriram D., (2005) Betulinic acid and its derivatives: A review on their biological properties. Curr Med Chem; 12: 657-666.
34. Chen Q.H., Fu M.L., Liu J., Zhang H.F., He G.Q., Ruan H., (2009) Optimization of ultrasonic-assisted extraction (UAE) of betulin from white birch bark using response surface methodology. Ultrason Sonochem; 16: 599-604.
35. Alakurtti S., Mäkelä T., Koskimies S., Yli-Kauhaluoma J., (2006) Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharm Sci; 29: 1-13.
36. Rzymowska J., (1998) The effect of aqueous extracts from Inonotus obliquus on the mitotic index and enzyme activities. Boll Chim Farm; 137: 13-15.
37. Kwon H.C., Min Y.D., Kim K.R., Bang E.J., Lee C.S., Lee K.R., (2003) A new acyl glycosyl sterol from Quisqualis. Arch Pharm Res; 26: 275-278.
38. Prakash Chaturvedula V.S., Schilling J.K., Johnson R.K., Kingston D.G., (2003) New cytotoxic lupane triterpenoids from the twigs of Coussarea paniculata. J Nat Prod; 66: 419-422.
39. Woldemichael G.M., Singh M.P., Maiese W.M., Timmermann B.N., (2003) Constituents of antibacterial extract of Caesalpinia paraguariensis. Z Naturforsch C; 58: 70-75.
40. Chandramu C., Manohar R.D., Krupadanam D.G., Dashavantha R.V., (2003) Isolation, characterization and biological activity of betulinic acid and ursolic acid from Vitex negundo L. Phytother Res; 17: 129-134.
41. Kim D.K., Nam I.Y., Kim J.W., Shin T.Y., Lim J.P., (2002) Pentacyclic triterpenoids from Ilex macropoda. Arch Pharm Res; 25: 617-620.
42. Yamashita K., Lu H., Lu J., Chen G., Yokoyama T., Sagara Y., Manabe M., Kodama H., (2002) Effect of three triterpenoids, lupeol, betulin, and betulinic acid on the stimulus-induced superoxide generation and tyrosyl phosphorylation of proteins in human neutrophils. Clin Chim Acta; 325: 91-96.
43. de Oliveira B.H., Santos C.A., Espíndola A.P., (2002) Determination of the triterpenoid, betulinic acid, in Doliocarpus schottianus by HPLC. Phytochem Anal; 13: 95-98.
44. Zhang Z., ElSohly H.N., Jacob M.R., Pasco D.S., Walker L.A., Clark A.M., (2002) Natural products inhibiting Candida albicans secreted aspartic proteases from Tovomita krukovii. Planta Med; 68: 49-54.
45. Guo X., Zhang L., Quan S., Hong Y., Sun L., Liu M., (1998) Isolation and identification of Triterpenoid compounds in the fruits of Chaenomeles lagenaria (Loisel.). Zhongguo Zhong Yao Za Zhi; 23: 546-547, 576.
46. Enwerem N.M., Okogun J.I., Wambebe C.O., Okorie D.A., Akah P.A., (2001) Anthelmintic activity of the stem bark extracts of Berlina grandiflora and one of its active principles, Betulinic acid. Phytomedicine; 8: 112-114.
47. Tezuka Y., Stampoulis P., Banskota A.H., Awale S., Tran K.Q., Saiki I., Kadota S., (2000) Constituents of the Vietnamese medicinal plant Orthosiphon. Chem Pharm Bull (Tokyo); 48: 1711-1719.
48. Siddiqui B.S., Sultana I., Begum S., (2000) Triterpenoidal constituents from Eucalyptus camaldulensis var. Obtusa leaves. Phytochemistry; 54: 861-865.
49. Kim Y.K., Yoon S.K., Ryu S.Y., (2000) Cytotoxic triterpenes from stem bark of Physocarpus intermedius. Planta Med; 66: 485-486.
50. Yi J.H., Zhang G.L., Li B.G., Chen Y.Z., (2000) Two glycosides from the stem bark of Tetracentron sinense. Phytochemistry; 53: 1001-1003.
51. Setzer W.N., Setzer M.C., Bates R.B., Jackes B.R., (2000) Biologically active triterpenoids of Syncarpia glomulifera bark extract from Paluma, north Queensland, Australia. Planta Med; 66: 176-177.
52. Banskota A.H., Tezuka Y., Adnyana I.K., Xiong Q., Hase K., Tran K.Q., Tanaka K., Saiki I., Kadota S., (2000) Hepatoprotective effect of Combretum quadrangulare and its constituents. Biol Pharm Bull; 23: 456-460.
53. Ma J., Starck S.R., Hecht S.M., (1999) DNA polymerase beta inhibitors from Tetracera boiviniana. J Nat Prod; 62: 1660-1663.
54. Schühly W., Heilmann J., Calis I., Sticher O., (1999) New triterpenoids with antibacterial activity from Zizyphus joazeiro. Planta Med; 65: 740-743.
55. Steele J.C., Warhurst D.C., Kirby G.C., Simmonds M.S., (1999) In vitro and in vivo evaluation of betulinic acid as an antimalarial. Phytother Res; 13: 115-119.
56. Krogh R., Kroth R., Berti C., Madeira A.O., Souza M.M., Cechinel-Filho V., Delle-Monache F., Yunes R.A., (1999) Isolation and identification of compounds with antinociceptive action from Ipomoea pes-caprae (L.) R. Br. Pharmazie; 54: 464-466.
57. Bringmann G., Saeb W., Assi L.A., François G., Sankara Narayanan A.S., Peters K., Peters E.M., (1997) Betulinic acid: Isolation from Triphyophyllum peltatum and Ancistrocladus heyneanus, antimalarial activity, and crystal structure of the benzyl ester. Planta Med; 63: 255-257.
58. Recio M.C., Giner R.M., Máñez S., Gueho J., Julien H.R., Hostettmann K., Ríos J.L., (1995) Investigations on the steroidal anti-inflammatory activity of triterpenoids from Diospyros leucomelas. Planta Med; 61: 9-12.
59. Fujioka T., Kashiwada Y., Kilkuskie R.E., Cosentino L.M., Ballas L.M., Jiang J.B., Janzen W.P., Chen I.S., Lee K.H., (1994) Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod; 57: 243-247.
60. Son L.B., Kaplun A.P., SpilevskѤ A.A., Andiia-Pravdivy E., Alekseeva S.G., Gribor'ev V.B., Shvets V.I., (1998) Synthesis of betulinic acid from betulin and study of its solubilisation using liposomes. Bioorg Khim; 24: 787-793.
61. Melnikova N., Burlova I., Kiseleva T., Klabukova I., Gulenova M., Kislitsin C.A., Vasin V., Tanaseichuk B.A., (2012) Practical synthesis of betulonic acid using selective oxidation of betulin on aluminium solid support. Molecules; 17: 11849-11863.
62. Mayaux J.F., Bousseau A., Pauwels R., Huet T., Hénin Y., Dereu N., Evers M., Soler F., Poujade C., De Clercq E., (1994) Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells. Proc Natl Acad Sci U S A; 91: 3564-3568.
63. Li F., Goila-Gaur R., Salzwedel K., Kilgore N.R., Reddick M., Matallana C., Castillo A., Zoumplis D., Martin D.E., Orenstein J.M., Allaway G.P., Freed E.O., Wild C.T., (2003) PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A; 100: 13555-13560.
64. Xu H.X., Zeng F.Q., Wan M., Sim K.Y., (1996) Anti-HIV triterpene acids from Geum japonicum. J Nat Prod; 59: 643-645.
65. Pengsuparp T., Cai L., Fong H.H., Kinghorn A.D., Pezzuto J.M., Wani M.C., Wall M.E., (1994) Pentacyclic triterpenes derived from Maprounea africana are potent inhibitors of HIV-1 reverse transcriptase. J Nat Prod; 57: 415-418.
66. de Sá M.S., Costa J.F., Krettli A.U., Zalis M.G., Maia G.L., Sette I.M., Câmara Cde A., Filho J.M., Giulietti-Harley A.M., Ribeiro Dos Santos R., Soares M.B., (2009) Antimalarial activity of betulinic acid and derivatives in vitro against Plasmodium falciparum and in vivo in P. berghei-infected mice. Parasitol Res; 105: 275-279.
67. Gautam R., Jachak S.M., (2009) Recent developments in anti-inflammatory natural products. Med Res Rev; 29: 767-820.
68. Pisha E., Chai H., Lee I.S., Chagwedera T.E., Farnsworth N.R., Cordell G.A., Beecher C.W., Fong H.H., Kinghorn A.D., Brown D.M., (1995) Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med; 1: 1046-1051.
69. Selzer E., Pimentel E., Wacheck V., Schlegel W., Pehamberger H., Jansen B., Kodym R., (2000) Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J Invest Dermatol; 114: 935-940.
70. Galgon T., Wohlrab W., Dräger B., (2005) Betulinic acid induces apoptosis in skin cancer cells and differentiation in normal human keratinocytes. Exp Dermatol; 14: 736-743.
71. Kessler J.H., Mullauer F.B., de Roo G.M., Medema J.P., (2007) Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types. Cancer Lett; 251: 132-145.
72. Laszczyk M.N., (2009) Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med; 75: 1549-1560.
73. Sun Y.F., Song C.K., Viernstein H., Unger F., Liang Z.S., (1998) Apoptosis of human breast cancer cells induced by microencapsulated betulinic acid from sour jujube fruits through the mitochondria transduction pathway. Food Chem; 138: 1998-2007.
74. Tiwari R., Puthli A., Balakrishnan S., Sapra B.K., Mishra K.P., (2014) Betulinic acid-induced cytotoxicity in human breast tumor cell lines MCF-7 and T47D and its modification by tocopherol. Cancer Invest; 32: 402-408.
75. Zuco V., Supino R., Righetti S.C., Cleris L., Marchesi E., Gambacorti-Passerini C., Formelli F., (2002) Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett; 175: 17-25.
76. Rzeski W., Stepulak A., Szymański M., Sifringer M., Kaczor J., Wejksza K., Zdzisińska B., Kandefer-Szerszeń M., (2006) Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells. Naunyn Schmiedebergs Arch Pharmacol; 374: 11-20.
77. Fulda S., Friesen C., Los M., Scaffidi C., Mier W., Benedict M., Nuñez G., Krammer P.H., Peter M.E., Debatin K.M., (1997) Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res; 57: 4956-4964.
78. Schmidt M.L., Kuzmanoff K.L., Ling-Indeck L., Pezzuto J.M., (1997) Betulinic acid induces apoptosis in human neuroblastoma cell lines. Eur J Cancer; 33: 2007-2010.
79. Fulda S., Jeremias I., Steiner H.H., Pietsch T., Debatin K.M., (1999) Betulinic acid: A new cytotoxic agent against malignant brain-tumor cells. Int J Cancer; 82: 435-441.
80. Wick W., Grimmel C., Wagenknecht B., Dichgans J., Weller M., (1999) Betulinic acidinduced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J Pharmacol Exp Ther; 289: 1306-1312.
81. Chintharlapalli S., Papineni S., Ramaiah S.K., Safe S., (2007) Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res; 67: 2816-2823.
82. Jung G.R., Kim K.J., Choi C.H., Lee T.B., Han S.I., Han H.K., Lim S.C., (2007) Effect of betulinic acid on anticancer drug-resistant colon cancer cells. Basic Clin Pharmacol Toxicol; 101: 277-285.
83. Aisha A.F., Abu-Salah K.M., Ismail Z., Majid A.M., (2012) alpha-Mangostin enhances betulinic acid cytotoxicity and inhibits cisplatin cytotoxicity on HCT 116 colorectal carcinoma cells. Molecules; 17: 2939-2954.
84. Noda Y., Kaiya T., Kohda K., Kawazoe Y., (1997) Enhanced cytotoxicity of sometriterpenes toward leukemia L1210 cells cultured in low pH media: Possibility of a new mode of cell killing. Chem Pharm Bull (Tokyo); 45: 1665-1670.
85. Ehrhardt H., Fulda S., Führer M., Debatin K.M., Jeremias I., (2004) Betulinicacid-induced apoptosis in leukemia cells. Leukemia; 18: 1406-1412.
86. Raghuvar Gopal D.V., Narkar A.A., Badrinath Y., Mishra K.P., Joshi D.S., (2005) Betulinicacid induces apoptosis in human chronic myelogenous leukemia (CML)cell line K-562 without altering the levels of Bcr-Abl. Toxicol Lett; 155: 343-351.
87. Thurnher D., Turhani D., Pelzmann M., Wannemacher B., Knerer B., Formanek M., Wacheck V., Selzer E., (2003) Betulinic acid: A new cytotoxic compound against malignant head and neck cancer cells. Head Neck; 25: 732-740.
88. Xu T., Pang Q., Zhou D., Zhang A., Luo S., Wang Y., Yan X., (2014) Proteomic investigation into betulinic acid-induced apoptosis of human cervical cancer HeLa cells. PLoS ONE; 9: E105768.
89. Reed J.C., (2002) Apoptosis-based therapies. Nat Rev Drug Discovery; 1: 111-121.
90. Fuchs Y., Steller H., (2011) Programmed cell death in animal development and disease. Cell; 147: 742-758.
91. Fulda S., Debatin K.M., (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene; 25: 4798-4811.
92. Sayers T.J., (2011) Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother; 60: 1173-1180.
93. Riedl S.J., Shi Y., (2004) Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol; 5: 897-907.
94. Pradelli L.A., Bénéteau M., Ricci J.E., (2010) Mitochondrial control of caspase-dependent and -independent cell death. Cell Mol Life Sci; 67: 1589-1597.
95. Tait S.W., Green D.R., (2010) Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol; 11: 621-632.
96. Bratton S.B., Salvesen G.S., (2010) Regulation of the Apaf-1-caspase-9 apoptosome. J Cell Sci; 123: 3209-3214.
97. Ferreira K.S., Kreutz C., Macnelly S., Neubert K., Haber A., Bogyo M., Timmer J., Borner C., (2012) Caspase-3 feeds back on caspase-8, Bid and XIAP in type I Fas signaling in primary mouse hepatocytes. Apoptosis; 17: 503-515.
98. Würstle M.L., Laussmann M.A., Rehm M., (2012) The central role of initiator caspase-9 in apoptosis signal transduction and the regulation of its activation and activity on the apoptosome. Exp Cell Res; 318: 1213-1220.
99. Reubold T.F., Eschenburg S., (2012) A molecular view on signal transduction by the apoptosome. Cell Signal; 24: 1420-1425.
100. Setzer W.N., Setzer M.C., (2003) Plant-derived triterpenoids as potential antineoplastic agents. Mini Rev Med Chem; 3: 540-556.
101. Shamas-Din A., Brahmbhatt H., Leber B., Andrews D.W., (2011) BH3-only proteins: Orchestrators of apoptosis. Biochim Biophys Acta; 1813: 508-520.
102. Czabotar P.E., Lessene G., Strasser A., Adams J.M., (2014) Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat Rev Mol Cell Biol; 15: 49-63.
103. Caroppi P., Sinibaldi F., Fiorucci L., Santucci R., (2009) Apoptosis and human diseases: Mitochondrion damage and lethal role of released cytochrome C as proapoptotic protein. Curr Med Chem; 16: 4058-4065.
104. Cory S., Adams J.M., (2002) The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer; 2: 647-656.
105. Villunger A., Michalak E.M., Coultas L., Müllauer F., Böck G., Ausserlechner M.J., Adams J.M., Strasser A., (2003) p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science; 302: 1036-1038.
106. Johnstone R.W., Ruefli A.A., Lowe S.W., (2002) Apoptosis: A link between cancer genetics and chemotherapy. Cell; 108: 153-164.
107. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., Green D.R., (2004) Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science; 303: 1010-1014.
108. Mahalingam D., Szegezdi E., Keane M., de Jong S., Samali A., (2009) TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev; 35: 280-288.
109. Orr G.A., Verdier-Pinard P., McDaid H., Horwitz S.B., (2003) Mechanisms of taxol resistance related to microtubules. Oncogene; 22: 7280-7295.
110. Puthalakath H., Huang D.C., O'Reilly L.A., King S.M., Strasser A., (1999) The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell; 3: 287-296.
111. Bouillet P., Metcalf D., Huang D.C., Tarlinton D.M., Kay T.W., Köntgen F., Adams J.M., Strasser A., (1999) Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude. Science; 286: 1735-1738.
112. Green D.R., Kroemer G., (2009) Cytoplasmic functions of the tumour suppressor p53. Nature; 458: 1127-1130.
113. Fulda S., (2008) Betulinic acid for cancer treatment and prevention. Int J Mol Sci; 9: 1096-1107.
114. Fulda S., (2009a) Betulinic acid: A natural product with anticancer activity. Mol Nutr Food Res; 53: 140-146.
115. Fulda S., Kroemer G., (2009) Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov Today; 14: 885-890.
116. Fulda S., Scaffidi C., Susin S.A., Krammer P.H., Kroemer G., Peter M.E., Debatin K.M., (1998) Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem; 273: 33942-33948.
117. Fulda S., Galluzzi L., Kroemer G., (2010) Targeting mitochondria for cancer therapy. Nat Rev Drug Discov; 9: 447-464.
118. Fulda S., (2015) Targeting apoptosis for anticancer therapy. Semin Cancer Biol; 31: 84-88.
119. Bhui K., Srivastava A.K., Shukla Y., (2010) Cytotoxic action of natural pentacyclic triterpenes on cancer cells: Lupane-type compounds. In:, Salvador J.A.R., editor. Pentacyclic Triterpenes as Promising Agents in Cancer. Hauppauge, NY, USA: Nova Science Publishers, Inc; p. 49-87.
120. Raisova M., Hossini A.M., Eberle J., Riebeling C., Wieder T., Sturm I., Daniel P.T., Orfanos C.E., Geilen C.C., (2001) The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol; 117: 333-340.
121. Rieber M., Strasberg Rieber M., (1998) Induction of p53 without increase in p21WAF1 in betulinic acid-mediated cell death is preferential for human metastatic melanoma. DNA Cell Biol; 17: 399-406.
122. Chakraborty B., Dutta D., Mukherjee S., Das S., Maiti N.C., Das P., Chowdhury C., (2015) Synthesis and biological evaluation of a novel betulinic acid derivative as an inducer of apoptosis in human colon carcinoma cells (HT-29). Eur J Med Chem; 102: 93-105.
123. Yang J., Qiu B., Li X., Zhang H., Liu W., (2015) p53-p66(shc)/miR-21-Sod2 signaling is critical for the inhibitory effect of betulinic acid on hepatocellular carcinoma. Toxicol Lett; 238: 1-10.
124. Foo J.B., Saiful Yazan L., Tor Y.S., Wibowo A., Ismail N., How C.W., Armania N., Loh S.P., Ismail I.S., Cheah Y.K., Abdullah R., (2015) Induction of cell cycle arrest and apoptosis by betulinic acid-rich fraction from Dillenia suffruticosa root in MCF-7 cells involved p53/p21 and mitochondrial signalling pathway. J Ethnopharmacol; 166: 270-278.
125. Yadav V.R., Prasad S., Sung B., Kannappan R., Aggarwal B.B., (2010) Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins (Basel); 2: 2428-2466.
126. Parrondo R., de las Pozas A., Reiner T., Rai P., Perez-Stable C., (2010) NF-kappaB activation enhances cell death by antimitotic drugs in human prostate cancer cells. Mol Cancer; 9: 182.
127. Hsu T.I., Wang M.C., Chen S.Y., Huang S.T., Yeh Y.M., Su W.C., Chang W.C., Hung J.J., (2012) Betulinic acid decreases specificity protein 1 (Sp1) level via increasing the sumoylation of Sp1 to inhibit lung cancer growth. Mol Pharmacol; 82: 1115-1128.
128. Killinger B., Shah M., Moszczynska A., (2014) Co-administration of betulinic acid and methamphetamine causes toxicity to dopaminergic and serotonergic nerve terminals in the striatum of late adolescent rats. J Neurochem; 128: 764-775.
129. Dang Z., Huang L., Chen C.H., (2009) HIV-1 maturation inhibitors: An update. Drug Future; 34: 797-802.
130. Lee K.H., (2010) Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach. J Nat Prod; 73: 500-516.
131. Blaževski J., Petkovic F., Momčilovic M., Paschke R., Kalud strok signerovic G.N., Mostarica Stojkovic M., Miljkovic D., (2013) Betulinic acid regulates generation of neuroinflammatory mediators responsible for tissue destruction in multiple sclerosis in vitro. Acta Pharmacol Sin; 34: 424-431.
132. Karna E., Szoka L., Palka J.A., (2010) Betulinic acid inhibits the expression of hypoxiainducible factor 1a and vascular endothelial growth factor in human endometrial adenocarcinoma cells. Mol Cell Biochem; 340: 15-20.
133. Dehelean C.A., Feflea S., Ganta S., Amiji M., (2011) Anti-angiogenic effects of betulinic acid administered in nanoemulsion formulation using chorioallantoic membrane assay. J Biomed Nanotechnol; 7: 317-324.
134. Chintharlapalli S., Papineni S., Lei P., Pathi S., Safe S., (2011) Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors. BMC Cancer; 11: 371.
135. Gao Y., Jia Z., Kong X., Li Q., Chang D.Z., Wei D., Le X., Suyun H., Huang S., Wang L., Xie K., (2011) Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res; 71: 5182-5193.
136. Mertens-Talcott S.U., Noratto G.D., Li X., Angel-Morales G., Bertoldi M.C., Safe S., (2013) Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: Role of Sp transcription factors and microRNA-27a:ZBTB10. Mol Carcinog; 52: 591-602.
137. Karna E., Palka J.A., (2009) Mechanism of betulinic acid inhibition of collagen biosynthesis in human endometrialadenocarcinoma cells. Neoplasma; 56: 361-366.
138. Mukherjee R., Jaggi M., Siddiqui M.J., Srivastava S.K., Rajendran P., Vardhan A., Burman A.C., (2004) Synthesis and cytotoxic activity of 3-O-acyl/3-hydrazine/2-bromo/20,29-dibromo betulinic acid derivatives. Bioorg Med Chem Lett; 14: 4087-4091.
139. Univerzita Karlova v Praze, Prirodovedecka Fakulta., Czech Rep, Univerzita Palackeho v Olomouci., Sarek J., Biedermann D., Hajduch M., Triterpenoid derivatives for treating tumor diseases and pharmaceutical composition in which the derivatives are comprised. CZ301158B6; 2009.
140. Spivak A.Y., Keiser J., Vargas M., Gubaidullin R.R., Nedopekina D.A., Shakurova E.R., Khalitova R.R., Odinokov V.N., (2013) Synthesis of lupane triterpenoids with triphenylphosphonium substituents and studies of their antitumor activity. Russ Chem Bull; 62: 188-198.
141. Zhang D.M., Xu H.G., Wang L., Li Y.J., Sun P.H., Wu X.M., Wang G.J., Chen W.M., Ye W.C., (2015) Betulinic acid and its derivatives as potential antitumor agents. Med Res Rev; 35: 1127-1155.
142. Casaroli-Marano R., Gallego-Pinazo R., Fernández-Blanco C.T., Figueroa M.S., Pina Marín B., Fernández-Baca Vaca G., Piñero-Bustamante A., Donate López J., García-Arumí J., Farrés Martí J., (2014) Age-related macular degeneration: Clinical findings following treatment with antiangiogenic drugs. J Ophthalmol; 2014: 346360.
143. Bar F.M., Khanfar M.A., Elnagar A.Y., Liu H., Zaghloul A.M., Badria F.A., Sylvester P.W., Ahmad K.F., Raisch K.P., El Sayed K.A., (2009) Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors. J Nat Prod; 72: 1643-1650.
144. Tripathi L., Kumar P., Singh R., (2009) A review on extraction, synthesis and anticancer activity of betulinic acid. Curr Bioact Compd; 5: 160-168.
145. Chen J.J., Patel A., Sodani K., Xiao Z.J., Tiwari A.K., Zhang D.M., Li Y.J., Yang D.H., Ye W.C., Chen S.D., Chen Z.S., (2013) BBA, a synthetic derivative of 23- hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10). PLoS ONE; 8: E74573.
146. Kommera H., Kaluderovic G.N., Kalbitz J., Dräger B., Paschke R., (2010) Small structural changes of pentacyclic lupane type triterpenoid derivatives lead to significant differences in their anticancer properties. Eur J Med Chem; 45: 3346-3353.
147. Reyes-Zurita F.J., Pachón-Peña G., Lizárraga D., Rufino-Palomares E.E., Cascante M., Lupiáñez J.A., (2011) The natural triterpene maslinic acid induces apoptosis in HT29 colon cancer cells by a JNK-p53-dependent mechanism. BMC Cancer; 11: 154.
148. Sankpal U.T., Goodison S., Abdelrahim M., Basha R., (2011) Targeting SP1 transcription factor in prostate cancer therapy. Med Chem; 7: 518-525.
149. Santos R.C., Salvador J.A., Cortés R., Pachón G., Marín S., Cascante M., (2011) New betulinic acid derivatives induce potent and selective antiproliferative activity through cell cycle arrest at the S phase and caspase dependent apoptosis in human cancer cells. Biochimie; 93: 1065-1075.
150. Sawada N., Kataoka K., Kondo K., Arimochi H., Fujino H., Takahashi Y., Miyoshi T., Kuwahara T., Monden Y., Ohnishi Y., (2004) Betulinic acid augments the inhibitory effects of vincristine on growth and lung metastasis of B16F10 melanoma cells in mice. Br J Cancer; 90: 1672-1678.
151. Sun Y.F., Song C.K., Viernstein H., Unger F., Liang Z.S., (2013) Apoptosis of human breast cancer cells induced by microencapsulated betulinic acid from sour jujube fruits through the mitochondria transduction pathway. Food Chem; 138: 1998-2007.
152. Yamai H., Sawada N., Yoshida T., Seike J., Takizawa H., Kenzaki K., Miyoshi T., Kondo K., Bando Y., Ohnishi Y., Tangoku A., (2009) Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. Int J Cancer; 125: 952-960.
153. Kommera H., Kaluderovic G.N., Bette M., Kalbitz J., Fuchs P., Fulda S., Mier W., Paschke R., (2010) In vitro anticancer studies of alpha and beta-d-glucopyranose betulin anomers. Chem Biol Interact; 185: 128-136.
154. Gheorgheosu D., Jung M., Ören B., Schmid T., Dehelean C., Muntean D., Brüne B., (2013) Betulinic acid suppresses NGAL-induced epithelial-to-mesenchymal transition in melanoma. Biol Chem; 394: 773-781.
155. Park S.Y., Kim H.J., Kim K.R., Lee S.K., Lee C.K., Park K.K., Chung W.Y., (2014) Betulinic acid, a bioactive pentacyclic triterpenoid, inhibits skeletal-related events induced by breast cancer bone metastases and treatment. Toxicol Appl Pharmacol; 275: 152-162.
156. Xu Y.P., Yang M., Pan D.H., (2011) Preparation of 131I-betulinic acid and its biodistribution in murine model of hepatocellular tumor. J Radioanal Nucl Chem; 288: 157-161.
157. Hata K., Hori K., Takahashi S., (2002) Differentiation- and apoptosis-inducing activities by pentacyclic triterpenes on a mouse melanoma cell line. J Nat Prod; 65: 645-648.
158. Liu W.K., Ho J.C., Cheung F.W., Liu B.P., Ye W.C., Che C.T., (2004) Apoptotic activity of betulinic acid derivatives on murine melanoma B16 cell line. Eur J Pharmacol; 498: 71-78.
159. Rajendran P., Jaggi M., Singh M.K., Mukherjee R., Burman A.C., (2008) Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. Invest New Drugs; 26: 25-34.
160. Willmann M., Wacheck V., Buckley J., Nagy K., Thalhammer J., Paschke R., Triche T., Jansen B., Selzer E., (2009) Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound. Eur J Clin Invest; 39: 384-394.
161. Fu J.Y., Qian L.B., Zhu L.G., Liang H.T., Tan Y.N., Lu H.T., Lu J.F., Wang H.P., Xia Q., (2011) Betulinic acid ameliorates endothelium-dependent relaxation in L-NAME-induced hypertensive rats by reducing oxidative stress. Eur J Pharm Sci; 44: 385-391.
162. Strüh C.M., Jäger S., Schempp C.M., Scheffler A., Martin S.F., (2012) A novel triterpene extract from mistletoe induces rapid apoptosis in murine B16.F10 melanoma cells. Phytother Res; 26: 1507-1512.
163. Soica C., Danciu C., Savoiu-Balint G., Borcan F., Ambrus R., Zupko I., Bojin F., Coricovac D., Ciurlea S., Avram S., Dehelean C.A., Olariu T., Matusz P., (2014) Betulinic acid in complex with a gamma-cyclodextrin derivative decreases proliferation and in vivo tumor development of non-metastatic and metastatic B164A5 cells. Int J Mol Sci; 15: 8235-8255.
164. Wang P., Li Q., Li K., Zhang X., Han Z., Wang J., Gao D., Li J., (2012) Betulinic acid exerts immunoregulation and anti-tumor effect on cervical carcinoma (U14) tumor-bearing mice. Pharmazie; 67: 733-739.
165. Wan Y., Wu Y.L., Lian L.H., Xie W.X., Li X., Ouyang B.Q., Bai T., Li Q., Yang N., Nan J.X., (2012) The anti-fibrotic effect of betulinic acid is mediated through the inhibition of NF-κB nuclear protein translocation. Chem Biol Interact; 195: 215-223.
166. Karpova M.B., Sanmun D., Henter J.I., Smirnov A.F., Fadeel B., (2006) Betulinic acid, a natural cytotoxic agent, fails to trigger apoptosis in human Burkitt's lymphoma-derived B-cell lines. Int J Cancer; 118: 246-252.
167. Patlolla J.M., Rao C.V., (2012) Triterpenoids for cancer prevention and treatment: Current status and future prospects. Curr Pharm Biotechnol; 13: 147-155.
168. Bache M., Zschornak M.P., Passin S., Kessler J., Wichmann H., Kappler M., Paschke R., Kalud strok signerovic G.N., Kommera H., Taubert H., Vordermark D., (2011) Increased betulinic acid induced cytotoxicity and radiosensitivity in glioma cells under hypoxic conditions. Radiat Oncol; 6: 111.
169. Zschornak M.P., Passin S., Kessler J., (2011) Effects of betulinic acid and irradiation on malignant glioma cells under normal and hypoxic conditions. Exp Strahlenther Klin Strahlenbiol; 20: 59-63.
170. Eder-Czembirek C., Erovic B.M., Czembirek C., Brunner M., Selzer E., Pötter R., Thurnher D., (2010) Betulinic acid a radiosensitizer in head and neck squamous cell carcinoma cell lines. Strahlenther Onkol; 186: 143-148.
171. Zhao Z., Wang J., Tang J., Liu X., Zhong Q., Wang F., Hu W., Yuan Z., Nie C., Wei Y., (2012) JNK and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells. Biochem J; 444: 291-301.
172. Wachsberger P.R., Burd R., Wahl M.L., Leeper D.B., (2002) Betulinic acid sensitization of low pH adapted human melanoma cells to hyperthermia. Int J Hyperthermia; 18: 153-164.
173. Li Q., Li Y., Wang X., Fang X., He K., Guo X., Zhan Z., Sun C., Jin Y.H., (2011) Co-treatment with ginsenoside Rh2 and betulinic acid synergistically induces apoptosis in human cancer cells in association with enhanced capsase-8 activation, bax translocation, and cytochrome c release. Mol Carcinog; 50: 760-769.
174. Eichenmüller M., Hemmerlein B., von Schweinitz D., Kappler R., (2010) Betulinic acid induces apoptosis and inhibits hedgehog signalling in rhabdomyosarcoma. Br J Cancer; 103: 43-51.
175. Del Valle E.M.M., Galán M.A., Carbonell R.G., (2009) Drug delivery technologies: The way forward in the new decade. Ind Eng Chem Res; 48: 2475-2486.
176. Hariharan R., Senthilkumar S., Suganthi A., Rajarajan M., (2012) Synthesis and characterization of doxorubicin modified ZnO/PEG nanomaterials and its photodynamic action. J Photochem Photobiol, B; 116: 56-65.
177. Saifullah B., Hussein M.Z., Hussein-Al-Ali S.H., Arulselvan P., Fakurazi S., (2013) Antituberculosis nanodelivery system with controlled-release properties based on para-amino salicylate-zinc aluminum-layered double-hydroxide nanocomposites. Drug Des Devel Ther; 7: 1365-1375.
178. Wong B.S., Yoong S.L., Jagusiak A., Panczyk T., Ho H.K., Ang W.H., Pastorin G., (2013) Carbon nanotubes for delivery of small molecule drugs. Adv Drug Deliv Rev; 65: 19640-20150.
179. Teunissen E.A., de Raad M., Mastrobattista E., (2013) Production and biomedical applications of virus-like particles derived from polyomaviruses. J Control Release; 172: 305-321.
180. Zeng Q., Wen H., Wen Q., Chen X., Wang Y., Xuan W., Liang J., Wan S., (2013) Cucumber mosaic virus as drug delivery vehicle for doxorubicin. Biomaterials; 34: 4632-4642.
181. Salomon J.J., Ehrhardt C., (2012) Organic cation transporters in the blood-air barrier: Expression and implications for pulmonary drug delivery. Ther Deliv; 3: 735-747.
182. T. C-L, C. K-H, S. W-Y, L. Y-H, W. C-C, L. F-H, (2013) Cationic gelatin nanoparticles for drug delivery to the ocular surface: In vitro and in vivo evaluation. J Nanomater; 2013: 1-11.
183. Teng W., Cappello J., Wu X., (2011) Physical crosslinking modulates sustained drug release from recombinant silk-elastinlike protein polymer for ophthalmic applications. J Control Release; 156: 186-194.
184. Hofer M., Winter G., Myschik J., (2012) Recombinant spider silk particles for controlled delivery of protein drugs. Biomaterials; 33: 1554-1562.
185. Cheng J., Meziani M.J., Sun Y.P., Cheng S.H., (2011) Poly(ethylene glycol)-conjugated multi-walled carbon nanotubes as an efficient drug carrier for overcoming multidrug resistance. Toxicol Appl Pharmacol; 250: 184-193.
186. Li R., Wu R., Zhao L., Hu Z., Guo S., Pan X., Zou H., (2011) Folate and iron difunctionalized multiwall carbon nanotubes as dual-targeted drug nanocarrier to cancer cells. Carbon; 49: 1797-1805.
187. Ji Z., Lin G., Lu Q., Meng L., Shen X., Dong L., Fu C., Zhang X., (2012) Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system. J Colloid Interface Sci; 365: 143-149.
188. Tan J.M., Govindarajan K., Palanisamy A., Sharida F., Hussein M.Z., (2014) Sustained release and cytotoxicity evaluation of carbon nanotube-mediated drug delivery system for betulinic acid. J Nanomater; 2014: 1-11.
189. Kaur R., Arora S., (2013) Interactions of betulinic acid with xenobiotic metabolizing and antioxidative enzymes in DMBA-treated Sprague Dawley female rats. Free Radic Biol Med; 65: 131-142.
190. Bori I.D., Hung H.Y., Qian K., Chen C.H., Morris-Natschke S.L., Lee K.H., (2012) Anti-AIDS agents 88. Anti-HIV conjugates of betulin and betulinic acid with AZT prepared via click chemistry. Tetrahedron Lett; 53: 1987-1989.
191. Liu Y., Ke Z., Wu K.Y., Liu S., Chen W.H., Jiang S., Jiang Z.H., (2011) An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation. ChemMedChem; 6: 1654-1664.
192. Effenberger K., Breyer S., Schobert R., (2010) Terpene conjugates of the Nigella sativa seed-oil constituent thymoquinone with enhanced efficacy in cancer cells. Chem Biodivers; 7: 129-139.
193. Wen Z., Martin D.E., Bullock P., Lee K.H., Smith P.C., (2007) Glucuronidation of anti-HIV drug candidate bevirimat: Identification of human UDP-glucuronosyltransferases and species differences. Drug Metab Dispos; 35: 440-448.
194. Xiong J., Kashiwada Y., Chen C.H., Qian K., Morris-Natschke S.L., Lee K.H., Takaishi Y., (2010) Conjugates of betulin derivatives with AZT as potent anti-HIV agents. Bioorg Med Chem; 18: 6451-6469.
195. Guo Z.R., (2012) Modification of natural products for drug discovery. Yao Xue Xue Bao; 47: 144-157.
196. Valli M., Pivatto M., Danuello A., Castro-Gamboa I., Silva D.H.S., Cavalheiro A.J., Araújo Â.R., Furlan M., Lopes M.N., Bolzani V.S., (2012) Tropical biodiversity: Has it been a potential source of secondary metabolites useful for medicinal chemistry? Quim Nova; 35: 2278-2287.
197. Kim D.S., Pezzuto J.M., Pisha E., (1998) Synthesis of betulinic acid derivatives with activity against human melanoma. Bioorg Med Chem Lett; 8: 1707-1712.
198. Gauthier C., Legault J., Lebrun M., Dufour P., Pichette A., (2006) Glycosidation of lupane-type triterpenoids as potent in vitro. Bioorg Med Chem; 14: 6713-6725.
199. Kvasnica M., Sarek J., Klinotova E., Dzubak P., Hajduch M., (2005) Synthesis of phthalates of betulinic acid and betulin with cytotoxic activity. Bioorg Med Chem; 13: 3447-3454.
200. Santos R.C., Salvador J.A., Marín S., Cascante M., (2009) Novel semisynthetic derivatives of betulin and betulinic acid with cytotoxic activity. Bioorg Med Chem; 17: 6241-6250.
201. You Y.J., Kim Y., Nam N.H., Ahn B.Z., (2003) Synthesis and cytotoxic activity of A-ring modified betulinic acid derivatives. Bioorg Med Chem Lett; 13: 3137-3140.
202. Koohang A., Majewski N.D., Szotek E.L., Mar A.A., Eiznhamer D.A., Flavin M.T., Xu Z.Q., (2009) Synthesis and cytotoxicity of 2-cyano-28-hydroxy-lup-1-en-3-ones. Bioorg Med Chem Lett; 19: 2168-2171.
203. Kumar V., Rani N., Aggarwal P., Sanna V.K., Singh A.T., Jaggi M., Joshi N., Sharma P.K., Irchhaiya R., Burman A.C., (2008) Synthesis and cytotoxic activity of heterocyclic ring-substituted betulinic acid derivatives. Bioorg Med Chem Lett; 18: 5058-5062.
204. Jeong H.J., Chai H.B., Park S.Y., Kim D.S., (1999) Preparation of amino acid conjugates of betulinic acid with activity against human melanoma. Bioorg Med Chem Lett; 9: 1201-1204.
205. Chatterjee P., Pezzuto J.M., Kouzi S.A., (1999) Glucosidation of betulinic acid by Cunninghamella species. J Nat Prod; 62: 761-763.
206. Kommera H., Kaluderovic G.N., Dittrich S., Kalbitz J., Dräger B., Mueller T., Paschke R., (2010) Carbamate derivatives of betulinic acid and betulin with selective cytotoxic activity. Bioorg Med Chem Lett; 20: 3409-3412.
207. Qian K., Kim S.Y., Hung H.Y., Huang L., Chen C.H., Lee K.H., (2011) New betulinic acid derivatives as potent proteasome inhibitors. Bioorg Med Chem Lett; 21: 5944-5947.
208. Suresh C., Zhao H., Gumbs A., Chetty C.S., Bose H.S., (2012) New ionic derivatives of betulinic acid as highly potent anti-cancer agents. Bioorg Med Chem Lett; 22: 1734-1738.
209. Baratto L.C., Porsani M.V., Pimentel I.C., Pereira Netto A.B., Paschke R., Oliveira B.H., (2013) Preparation of betulinic acid derivatives by chemical and biotransformation methods and determination of cytotoxicity against selected cancer cell lines. Eur J Med Chem; 68: 121-131.
210. Drag-Zalesinska M., Kulbacka J., Saczko J., Wysocka T., Zabel M., Surowiak P., Drag M., (2009) Esters of betulin and betulinic acid with amino acids have improved water solubility and are selectively cytotoxic toward cancer cells. Bioorg Med Chem Lett; 19: 4814-4817.
211. Drag M., Surowiak P., Drag-Zalesinska M., Dietel M., Lage H., Oleksyszyn J., (2009) Comparison of the cytotoxic effects of birch bark extract, betulin and betulinic acid towards human gastric carcinoma and pancreatic carcinoma drug-sensitive and drug-resistant cell lines. Molecules; 14: 1639-1651.
212. Drąg-Zalesińska M., Wysocka T., Borska S., Drąg M., Poręba M., Choromańska A., Kulbacka J., Saczko J., (2015) The new esters derivatives of betulin and betulinic acid in epidermoid squamous carcinoma treatment-in vitro studies. Biomed Pharmacother; 72: 91-97.
213. Ding W., Sun M., Luo S., Xu T., Cao Y., Yan X., Wang Y., (2013) A 3D QSAR study of betulinic acid derivatives as anti-tumor agents using topomer CoMFA: Model building studies and experimental verification. Molecules; 18: 10228-10241.